ECSP066432A - Moléculas de enlace terapéuticas - Google Patents

Moléculas de enlace terapéuticas

Info

Publication number
ECSP066432A
ECSP066432A EC2006006432A ECSP066432A ECSP066432A EC SP066432 A ECSP066432 A EC SP066432A EC 2006006432 A EC2006006432 A EC 2006006432A EC SP066432 A ECSP066432 A EC SP066432A EC SP066432 A ECSP066432 A EC SP066432A
Authority
EC
Ecuador
Prior art keywords
ser
asn
amino acid
acid sequence
cdr2
Prior art date
Application number
EC2006006432A
Other languages
English (en)
Inventor
Jose Saldanha
Frank Kolbinger
Herrera Jose M Carballido
Andras Aszodi
Bruce M Hall
Silvia Gregori
Maria Grazia Roncarolo
Veronique Loux
Gregorio Aversa
Margit Jeschke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/666,332 external-priority patent/US20050069538A1/en
Priority claimed from GB0414309A external-priority patent/GB0414309D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066432A publication Critical patent/ECSP066432A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una molécula que comprende por lo menos un sitio de enlace de antígeno, que comprende en secuencia las regiones hipervariables CDR1, CDR2 y CDR3, dicha CDR1 tiene la secuencia de aminoácido Asn-Tyr-Ile-IIe-His (NYIIH), dicha CDR2 tiene la secuencia de aminoácido Tyr-Phe-Asn-ProTyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) y dicha CDR3 tiene la secuencia de aminoácido Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); por ejemplo, además comprende en secuencia las regiones hipervariables CDR1', CDR2' y CDR3', CDR1' tiene la secuencia de aminoácido Arg-Ala-Ser-Gln-Asn-Ile-GIy-ThrSer-IIe-Gln (RASQNIGTSIQ), CDR2' tiene la secuencia de aminoácido Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) y CDR3' tiene la secuencia de aminoácido Gln-GIn-Ser-Asn-Thr-Trp Pro-Phe-Thr (QQSNTWPFT), por ejemplo un anticuerpo quimérico o humanizado, útil como un farmacéutico.
EC2006006432A 2003-09-18 2006-03-17 Moléculas de enlace terapéuticas ECSP066432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/666,332 US20050069538A1 (en) 2003-09-18 2003-09-18 Therapeutic binding molecules
GB0414309A GB0414309D0 (en) 2004-06-25 2004-06-25 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP066432A true ECSP066432A (es) 2006-09-18

Family

ID=34315457

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006432A ECSP066432A (es) 2003-09-18 2006-03-17 Moléculas de enlace terapéuticas

Country Status (28)

Country Link
EP (1) EP1664122B1 (es)
JP (1) JP4762142B2 (es)
KR (1) KR20060079232A (es)
AR (2) AR045765A1 (es)
AT (1) ATE461219T1 (es)
AU (1) AU2004272289B2 (es)
BR (1) BRPI0414515A (es)
CA (1) CA2537217A1 (es)
CY (1) CY1110033T1 (es)
DE (1) DE602004026081D1 (es)
DK (1) DK1664122T3 (es)
EC (1) ECSP066432A (es)
ES (1) ES2341341T3 (es)
HR (1) HRP20100334T1 (es)
IL (1) IL173820A0 (es)
IS (1) IS8397A (es)
MA (1) MA28041A1 (es)
MY (1) MY143963A (es)
NO (1) NO20061681L (es)
NZ (1) NZ545605A (es)
PE (1) PE20060019A1 (es)
PL (1) PL1664122T3 (es)
PT (1) PT1664122E (es)
RU (1) RU2386639C2 (es)
SI (1) SI1664122T1 (es)
TN (1) TNSN06087A1 (es)
TW (1) TW200521231A (es)
WO (1) WO2005026210A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
TWI579722B (zh) * 2015-02-17 2017-04-21 陳沛隆 藥物不良反應風險評估方法及其裝置
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
JP2023535727A (ja) * 2020-07-24 2023-08-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ＳＩＲＰα媒介性シグナル伝達を調節するための組成物及び方法
CA3198049A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
EP4433512A4 (en) 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170256C2 (ru) * 1991-07-25 2001-07-10 Айдек Фармасьютикалс Корпорейшн Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20060079232A (ko) 2006-07-05
IS8397A (is) 2006-04-03
AR045765A1 (es) 2005-11-09
JP4762142B2 (ja) 2011-08-31
PL1664122T3 (pl) 2010-08-31
NO20061681L (no) 2006-06-13
RU2386639C2 (ru) 2010-04-20
EP1664122A2 (en) 2006-06-07
HRP20100334T1 (hr) 2010-07-31
TNSN06087A1 (en) 2007-10-03
ES2341341T3 (es) 2010-06-18
PE20060019A1 (es) 2006-02-27
WO2005026210A3 (en) 2005-07-14
MY143963A (en) 2011-07-29
AR079458A2 (es) 2012-01-25
CA2537217A1 (en) 2005-03-24
NZ545605A (en) 2009-03-31
DK1664122T3 (da) 2010-06-28
AU2004272289B2 (en) 2008-09-18
IL173820A0 (en) 2006-07-05
TW200521231A (en) 2005-07-01
HK1091844A1 (en) 2007-01-26
WO2005026210A2 (en) 2005-03-24
BRPI0414515A (pt) 2006-11-07
SI1664122T1 (sl) 2010-07-30
MA28041A1 (fr) 2006-07-03
AU2004272289A1 (en) 2005-03-24
EP1664122B1 (en) 2010-03-17
ATE461219T1 (de) 2010-04-15
DE602004026081D1 (de) 2010-04-29
RU2006112598A (ru) 2007-10-27
PT1664122E (pt) 2010-05-10
CY1110033T1 (el) 2015-01-14
JP2007529196A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
BR0207151A (pt) Moléculas de aglutinação terapêuticas
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
AR035581A1 (es) Anticuerpos para il-1beta humana
BR0112086A (pt) Anticorpos para mcp-1 humano
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
GEP20074222B (en) Antibodies to cd40
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
PE20110797A1 (es) Anticuerpos anti mn
CO5280086A1 (es) Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica
TW200716182A (en) Antibodies directed to CD20 and uses thereof
ATE417067T1 (de) Rs7 antikörper
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2006039258A3 (en) Human antibodies against parathyroid hormone
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
AR046094A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
DK1100829T3 (da) Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme